The European Patent Office (EPO) has published patent application EP4230651A1, titled "Testosterone-Specific Affibody and Uses Thereof." The application, filed by Inssen Inc., details a specific affibody designed to bind with testosterone and outlines its potential applications. This publication is part of the EPO's regular bulletin and does not impose new regulatory obligations but rather announces the availability of patent information.

Compliance officers in the pharmaceutical and biotechnology sectors should note this publication as it pertains to intellectual property within the European Union. While this is a patent publication and not a regulatory rule, it may indicate emerging technologies or product development areas that could be relevant for competitive analysis or future regulatory considerations. No immediate compliance actions are required based on this patent publication.